Merck & Co. Inc (MRK) Closes 1.56% Down on the Day for January 06

Equities Staff |

Dow Jones component Merck & Co. Inc (MRK) saw its stock move -1.56% to $52.32, representing a per-share move of $0.83, on volume of 8.97 million shares for Wednesday.

Merck & Co. Inc currently has a total float of 2.79 billion shares and moves 10.2 million a day, on average. The stock opened at $52.51 on January 06 and traded between a low of $52.21 and a high of $52.95. The stock now has a 50-day SMA of $53.24 and 200-day SMA of $54.94, and it has a high of $63.62 and low of $45.69 over the last year. Its P/E ratio is 14.3 and its P/B ratio is 3.21.

Merck & Co Inc is a health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products.

Based out of Kenilworth, NJ, Merck & Co. Inc has 70,000 employees and is helmed by CEO Kenneth C. Frazier.

For a deeper dive into the fundamentals of Merck & Co. Inc, check out equities.com’s E.V.A. report for MRK.

GET TO KNOW THE DOW

The Dow Jones Industrial Average is the oldest and most-often cited stock market index for the American equities market. While it’s arguably outdated and inefficient, it remains the most visible representation of the stock market to the outside world. Consisting of 30 companies selected by the editorial board of the Wall Street Journal, it’s meant to give an overview of stock performances by looking at a slice of those mega- and large-cap companies deemed to best represent the broad economy.

The history of the index dates all the way back to 1896 when it was first created by Charles Dow, the legendary founding editor of the Wall Street Journal and founder of Dow Jones & Company, and Edward Jones, a statistician. The price-weighted, scaled index has since become a standard part of most major daily news recaps and has seen dozens of different companies pass through its ranks, with only General Electric (GE) remaining on the index since its inception.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

Beleave Inc.

Beleave Inc is a biotech company. The Company is engaged in the production of medical marijuana under the Marihuana for Medical Purposes Regulations outlined by Health Canada.

Private Markets

WayBetter

The spark hit Jamie when he saw co-workers competing to lose weight. Instead of pizzas and subs, they were eating salads and jogging along the river. Some were sneakily leaving…

Wealthfront

Wealthfront is an automated investment service that serves as an alternative to traditional financial advisory services. The company manages a diversified, continually rebalanced portfolio of index funds on their clients’…